85 recruiting, 62 completed, 52 terminated, 45 unknown. 303 Phase 2, 200 Phase 1, 2 Phase 3.
Follow Solid Tumor: new trials by email Literature Review of Solid Tumor trials Research Report on Solid Tumor
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Targeting CD276 (B7-H3) Positive Solid Tumors by 4SCAR-276 4SCAR-276 - Solid Tumor | Phase 1 / Phase 2 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 100 | 2027-06-01 | 2026-11-02 |
| A Phase 1/2 Trial Of Larotrectinib And Pembrolizumab In Patients With Solid Tumors Previously Treated With Immune Checkpoint Inhibitor Monotherapy Larotrectinib, Pembrolizumab - Solid Tumor | Phase 1 / Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | 22 | 2027-03-01 | 2026-09-28 |
| Mirdametinib to Reduce the Size of Large/Giant Congenital Melanocytic Nevi in Children, Adolescents and Young Adults Mirdametinib - LGCMN, Large and Giant Congenital Melanocytic Nevi | Phase 2 | Not yet recruiting | National Cancer Institute (NCI) | 15 | 2027-01-04 | 2026-10-29 |
| GD2/PSMA Bi-specific CAR-T Cell Therapy bi-4SCAR GD2/PSMA T cells - Solid Tumor | Phase 1 / Phase 2 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 60 | 2026-12-31 | 2026-11-02 |
| Study on GD2 Positive Solid Tumors by 4SCAR-GD2 4SCAR-GD2 - Solid Tumor | Phase 1 / Phase 2 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 10 | 2026-12-31 | 2026-10-30 |
| SumMET: Study of [225Ac]Ac-FL-261 in Participants With Solid Tumors Overexpressing c-MET [225Ac]Ac-FL-261 - Solid Tumor, NSCLC | Phase 1 / Phase 2 | Recruiting | Full-Life Technologies UK Limited | 208 | 2026-12-01 | 2026-11-16 |
| A Phase Ib/II Study of BM230 in Combination With PD-1 Inhibitor for HER2-related Advanced Solid Tumors BM230 & PD-1 inhibitor - Solid Tumor | Phase 1 / Phase 2 | Not yet recruiting | Suzhou Biomissile Pharmaceuticals Co., Ltd. | 90 | 2026-11-01 | 2026-10-09 |
| A Clinical Trial on the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-9308 Tablet as Monotherapy or Combination Therapy in Participants With Advanced Solid Tumors HRS-9308 Tablet - Solid Tumor | Phase 1 / Phase 2 | Not yet recruiting | Chengdu Suncadia Medicine Co., Ltd. | 126 | 2026-11-01 | 2026-11-16 |
| A Study of Tagmokitug in Combination With Other Treatments in Participants With Advanced or Metastatic Solid Tumors Tagmokitug, Pasritamig - Solid Tumor | Phase 1 / Phase 2 | Recruiting | Coherus Oncology, Inc. | 12 | 2026-11-01 | 2026-11-18 |
| A Study of DS-3939a in Participants With Solid Tumors DS-3939a, Pembrolizumab, Carboplatin - Solid Tumor, Locally Advanced Non-Small Cell Lung Cancer | Phase 1 / Phase 2 | Recruiting | Daiichi Sankyo | 400 | 2026-10-13 | 2026-11-10 |
| Olaparib in the Treatment of BRCA1/2 Unmutated and BRCA1 Promoter Methylated Recurrent and Metastatic Triple-negative Breast Cancer Olaparib - Solid Tumor | Phase 2 | Not yet recruiting | Hebei Medical University Fourth Hospital | 30 | 2026-09-01 | 2025-12-11 |
| A Study of FG-B901 Monotherapy or Combination With Chemotherapy in Advanced or Metastatic Solid Tumors FG-B901, standard or investigator-determined chemotherapy - Solid Tumor | Phase 1 / Phase 2 | Not yet recruiting | FutureGen Biopharmaceutical (Beijing) Co., Ltd | 264 | 2026-07-01 | 2026-06-03 |
| Clinical Study of the Safety and Efficacy of Allogeneic TCR-enhanced Vδ2 T Cell in Patients With Malignant Tumors. Allogeneic TCR-enhanced Vδ2 T cell Injection, Cyclophosphamide injection, Fludarabine Injection - Hematologic Malignancy, Solid Tumor | Phase 1 / Phase 2 | Recruiting | Chinese PLA General Hospital | 24 | 2026-06-05 | 2026-06-08 |
| Study of IBI3005 Combination Therapy in Participants With Unresectable, Locally Advanced or Metastatic Solid Tumors IBI3005, Sintilimab, Bevacizumab biosimilar - Solid Tumor | Phase 1 / Phase 2 | Not yet recruiting | Innovent Biologics (Suzhou) Co. Ltd. | 282 | 2026-06-01 | 2026-05-28 |
| A Study to Evaluate the Safety and Diagnostic Performance of F18 FBPA PET/CT Imaging in Solid Tumors F18 FBPA Injection - Solid Tumor | Phase 1 / Phase 2 | Recruiting | Heron Neutron Medical Corp. | 30 | 2026-05-20 | 2026-07-09 |
| A Clinical Study of HRS-8364 in the Treatment of Advanced Solid Tumor Subjects HRS-8364 Tablet - Solid Tumor | Phase 1 / Phase 2 | Recruiting | Jiangsu HengRui Medicine Co., Ltd. | 282 | 2026-03-19 | 2026-04-03 |
| Atamparib in Patients With Advanced Solid Tumors atamparib escalation levels, atamparib RP2D - NSCLC Adenocarcinoma, Solid Tumor | Phase 1 / Phase 2 | Recruiting | Nerviano Medical Sciences (Shanghai) Ltd. | 178 | 2026-03-18 | 2026-07-29 |
| A IB/II Phase Clinical Study on the Safety, Tolerability, and Efficacy of SHR-9839(sc) in Combination Anti-tumor Therapy in Patients With Solid Tumors SHR-9839(sc) For Injection - Solid Tumor | Phase 1 / Phase 2 | Recruiting | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 70 | 2026-02-27 | 2026-03-20 |
| SB-4826 in Adult Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphomas SB-4826, Rituximab - Non Hodgkin Lymphoma, Solid Tumor | Phase 1 / Phase 2 | Recruiting | University of California, San Diego | 48 | 2026-02-18 | 2026-03-05 |
| Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2) Givastomig, Nivolumab, 5Fluorouracil - Solid Tumor, Advanced Cancer | Phase 2 | Recruiting | I-Mab Biopharma US Limited | 180 | 2026-02-11 | 2026-05-14 |
Showing 20 of 303. Sign in to see all of them.
Neoplasms (41) · Carcinoma, Non-Small-Cell Lung (38) · Colorectal Neoplasms (29) · Melanoma (26) · Neoplasm Metastasis (24) · Stomach Neoplasms (21) · Ovarian Neoplasms (19) · Breast Neoplasms (17) · Endometrial Neoplasms (17) · Pancreatic Neoplasms (16) · Head and Neck Neoplasms (14) · Lung Neoplasms (14) · Lymphoma (14) · Carcinoma, Renal Cell (13) · Squamous Cell Carcinoma of Head and Neck (12)
Neoplasms (138) · Neoplasms by Site (134) · Neoplasms by Histologic Type (90) · Digestive System Diseases (62) · Digestive System Neoplasms (62) · Neoplasms, Glandular and Epithelial (58) · Gastrointestinal Diseases (54) · Gastrointestinal Neoplasms (51) · Urogenital Diseases (51) · Urogenital Neoplasms (51) · Lung Diseases (50) · Respiratory Tract Diseases (50) · Female Urogenital Diseases (49) · Female Urogenital Diseases and Pregnancy Complications (49) · Respiratory Tract Neoplasms (49)
pembrolizumab (30) · Nivolumab (22) · Paclitaxel (11) · Ipilimumab (10) · Cisplatin (9) · atezolizumab (9) · Gemcitabine (8) · Injections (8) · toripalimab (8) · Capecitabine (7) · Fluorouracil (7) · Carboplatin (6) · Cyclophosphamide (6) · Docetaxel (6) · Cetuximab (5)
Chinese PLA General Hospital (6) · Memorial Sloan Kettering Cancer Center (6) · Eli Lilly and Company (5) · Jiangsu HengRui Medicine Co., Ltd. (5) · BioNTech SE (4) · Innovent Biologics (Suzhou) Co. Ltd. (4) · M.D. Anderson Cancer Center (4) · Samsung Medical Center (4) · Sichuan Baili Pharmaceutical Co., Ltd. (4) · Allist Pharmaceuticals, Inc. (3) · Binhui Biopharmaceutical Co., Ltd. (3) · Dana-Farber Cancer Institute (3) · Gilead Sciences (3) · National Cancer Institute (NCI) (3) · National University Hospital, Singapore (3)
United States (149) · China (102) · Spain (31) · South Korea (26) · Australia (25) · France (23) · United Kingdom (15) · Canada (14) · Belgium (11) · Italy (11) · Taiwan (11) · Japan (9) · Netherlands (9) · Germany (7) · Singapore (7)
Dingwei Ye, PHD (2) · Ely Benaim, MD (2) · Jason Wu (2) · Li Zhang (2) · Lin Shen, MD (2) · Michael Ortiz, MD (2) · Raghav Sundar (2) · Zhengbo Song (2) · Adam Crystal, MD, PhD (1)
PMID 42413526, PMID 42636835, PMID 21739119, PMID 24523121, PMID 25086465, PMID 26095785, PMID 26984445, PMID 26984449, PMID 27053773, PMID 27240885, PMID 27627808, PMID 28196905, PMID 28330462, PMID 28972963, PMID 29188469, PMID 30089632, PMID 30094065, PMID 30227893, PMID 30420614, PMID 31401903, PMID 31753029, PMID 31771394, PMID 31780255, PMID 31812554, PMID 31953313, PMID 32107712, PMID 32108102, PMID 32503469, PMID 33431660, PMID 33602696, PMID 33634869, PMID 34154614, PMID 34230007, PMID 34301808, PMID 34301809, PMID 34713106, PMID 34757194, PMID 34951522, PMID 35165764, PMID 35176457, PMID 35385748, PMID 35633184, PMID 35660797, PMID 35724798, PMID 35833116, PMID 35892341, PMID 35920783, PMID 35923928, PMID 36062046, PMID 36156099
2023 (7), 2018 (6), 2019 (4), 2014 (3), 2015 (2), 2016 (1), P30CA012197 (1), P30CA016059 (1), R44CA265656 (1)